.png)
Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on Caprelsa (vandetanib) - Direct communication with healthcare professionals on Caprelsa (vandetanib)
Direct communication with healthcare professionals on Caprelsa (vandetanib)
Summary
- Vandetanib should not be administered to patients in whom rearranged during transfection (RET) mutation status is not known or is negative.
- Restriction of the indication is based on data from the randomized study D4500C00058, and the observational study OBS14778, showing insufficient activity of vandetanib in patients with no identified RET mutations.
- Prior to initiation of treatment with vandetanib, the presence of a RET mutation should be determined by a validated test.
- For patients currently under treatment and for which the RET status remains unknown or is negative, healthcare professionals are recommended to discontinue treatment taking into account their judgement of the patients’ clinical response and the best treatment available.
Published on: 14 December 2022
AIFA e Procura di Velletri firmano il protocollo d’intesa per il contrasto alla violenza di genere
...
Vai al post →
💊 Se non sei un medico, non fare il medico. L’uso improprio degli #antibiotici ne limita l’efficaci...
Vai al post →
💊 Se non sei un medico, non fare il medico. L’uso improprio degli #antibiotici ne limita l’efficaci...
Vai al post →
📅 #1dicembre - Giornata mondiale della lotta contro l’AIDS
🔴 #AIFA si illumina di rosso, colore s...
Vai al post →
🔬 Secondo Bando #AIFA di ricerca indipendente 2025
📑 107 progetti presentati, per un finanziament...
Vai al post →
👥💬 Parte “AIFA Ascolta”, uno spazio di dialogo con associazioni, reti e federazioni dei #pazienti,...
Vai al post →
